Therapeutic Potential of Phycocyanin in Gastrointestinal Cancers and Related Disorders Publisher Pubmed



Motamedzadeh A¹ ; Rahmatidehkordi F^{2, 3} ; Heydari H⁴ ; Behnam M⁵ ; Rashidi Noshabad FZ⁵ ; Tamtaji Z⁵ ; Taheri AT⁶ ; Nabavizadeh F^{2, 3} ; Aschner M⁷ ; Mirzaei H^{8, 9} ; Tamtaji OR^{2, 3, 9}
Source: Molecular Biology Reports Published:2024

Abstract

Gastrointestinal cancer is the most fatal cancer worldwide. The etiology of gastrointestinal cancer has yet to be fully characterized. Alcohol consumption, obesity, tobacco, Helicobacter pylori and gastrointestinal disorders, including gastroesophageal reflux disease, gastric ulcer, colon polyps and non-alcoholic fatty liver disease are among the several risks factors for gastrointestinal cancers. Phycocyanin which is abundant in Spirulina. Phycocyanin, a member of phycobiliprotein family with intense blue color, is an anti-diabetic, neuroprotective, anti-oxidative, anti-inflammatory, and anticancer compound. Evidence exists supporting that phycocyanin has antitumor effects, exerting its pharmacological effects by targeting a variety of cellular and molecular processes, i.e., apoptosis, cell-cycle arrest, migration and Wnt/β-catenin signaling. Phycocyanin has also been applied in treatment of several gastrointestinal disorders such as, gastric ulcer, ulcerative colitis and fatty liver that is known as a risk factor for progression to cancer. Herein, we summarize various cellular and molecular pathways that are affected by phycocyanin, its efficacy upon combined drug treatment, and the potential for nanotechnology in its gastrointestinal cancer therapy. © The Author(s), under exclusive licence to Springer Nature B.V. 2024.